Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P35125
UPID:
UBP6_HUMAN
Alternative names:
Deubiquitinating enzyme 6; Proto-oncogene TRE-2; Ubiquitin thioesterase 6; Ubiquitin-specific-processing protease 6
Alternative UPACC:
P35125; Q15634; Q86WP6; Q8IWT4
Background:
Ubiquitin carboxyl-terminal hydrolase 6, known by alternative names such as Deubiquitinating enzyme 6 and Ubiquitin-specific-processing protease 6, plays a pivotal role in cellular processes. It exhibits ATP-independent isopeptidase activity, targeting the C-terminus of ubiquitin moieties for cleavage and catalyzing its own deubiquitination. Notably, isoform 2 demonstrates deubiquitinating activity in vitro, distinguishing it from isoform 3. This enzyme is crucial for the plasma membrane localization of ARF6 and selectively modulates ARF6-dependent endocytic protein trafficking. Its ability to initiate tumorigenesis by activating NF-kappa-B and inducing matrix metalloproteinases production underscores its biological significance.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 6 could open doors to potential therapeutic strategies.